P M Carpenter

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Angiogenesis in the progression of breast ductal proliferations
    Philip M Carpenter
    Department of Pathology and Laboratory Medicine, University of California, Irvine Medical Center, 101 The City Dr, Orange, CA 92868, USA
    Int J Surg Pathol 19:335-41. 2011
  2. ncbi Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha
    P M Carpenter
    Department of Pathology, University of California, Irvine 92868, USA
    Int J Cancer 71:64-70. 1997
  3. ncbi Mammary epithelium-induced motility of MCF-7 cells
    P M Carpenter
    Department Pathology, University of California, Irvine Medical Center, Orange, CA 92868, USA
    Anticancer Res 18:1063-8. 1998
  4. ncbi Laminin 5 expression in metaplastic breast carcinomas
    Philip M Carpenter
    The Department of Pathology and Laboratory Medicine, The University of California, Orange, CA 92868, USA
    Am J Surg Pathol 32:345-53. 2008
  5. ncbi Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5)
    Philip M Carpenter
    Department of Pathology and Laboratory Medicine, University of California, Orange, CA 92868, USA
    Mol Cancer Res 7:462-75. 2009
  6. ncbi Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin
    Philip M Carpenter
    Department of Pathology, Irvine Medical Center, University of California, Building 10, Route 40, Room 104, 101 The City Drive South, Orange, CA 92868, USA
    Cancer Epidemiol Biomarkers Prev 13:1996-2002. 2004
  7. ncbi The role of hyaluronan in mesothelium-induced motility of ovarian carcinoma cells
    Philip M Carpenter
    Department of Pathology, Building 10, Route 40, Room 104, University of California, Irvine Medical Center, 101 The City Dr, Orange, CA 92868, USA
    Anticancer Res 23:3985-90. 2003
  8. ncbi Reversible transformation by v-sis: a model cell line for analysis of transformation by antisense methods
    P M Carpenter
    Department of Pathology, University of California, San Diego, La Jolla 92093
    Antisense Res Dev 1:289-95. 1991
  9. ncbi Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
  10. ncbi Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli
    Rita S Mehta
    Department of Internal Medicine, University of California, Irvine, CA, USA
    Clin Breast Cancer 9:56-9. 2009

Collaborators

Detail Information

Publications22

  1. ncbi Angiogenesis in the progression of breast ductal proliferations
    Philip M Carpenter
    Department of Pathology and Laboratory Medicine, University of California, Irvine Medical Center, 101 The City Dr, Orange, CA 92868, USA
    Int J Surg Pathol 19:335-41. 2011
    ..This study shows that the first significant increase in angiogenesis occurs very early in the evolution of ductal proliferations as ductal cells become hyperplastic...
  2. ncbi Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha
    P M Carpenter
    Department of Pathology, University of California, Irvine 92868, USA
    Int J Cancer 71:64-70. 1997
    ..Our results raise the possibility that TNF-alpha-induced motility is one mechanism by which tumor cells overcome the potential anti-tumor immune function of lymphocytes and macrophages in peri-tumoral infiltrates...
  3. ncbi Mammary epithelium-induced motility of MCF-7 cells
    P M Carpenter
    Department Pathology, University of California, Irvine Medical Center, Orange, CA 92868, USA
    Anticancer Res 18:1063-8. 1998
    ..Cancer cell invasion may be mediated by motility factors elaborated by the surrounding normal host tissue. This study was performed to determine whether normal breast cells induce motility in breast cancer...
  4. ncbi Laminin 5 expression in metaplastic breast carcinomas
    Philip M Carpenter
    The Department of Pathology and Laboratory Medicine, The University of California, Orange, CA 92868, USA
    Am J Surg Pathol 32:345-53. 2008
    ..Further study of other basal-like tumors for laminin 5 expression is warranted to determine the usefulness of laminin 5 in their diagnosis...
  5. ncbi Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5)
    Philip M Carpenter
    Department of Pathology and Laboratory Medicine, University of California, Orange, CA 92868, USA
    Mol Cancer Res 7:462-75. 2009
    ....
  6. ncbi Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin
    Philip M Carpenter
    Department of Pathology, Irvine Medical Center, University of California, Building 10, Route 40, Room 104, 101 The City Drive South, Orange, CA 92868, USA
    Cancer Epidemiol Biomarkers Prev 13:1996-2002. 2004
    ..Following these changes during a skin cancer chemopreventative trial can then help assess the efficacy of the agent and help determine where in the progression of neoplastic changes it exerts its biological effects...
  7. ncbi The role of hyaluronan in mesothelium-induced motility of ovarian carcinoma cells
    Philip M Carpenter
    Department of Pathology, Building 10, Route 40, Room 104, University of California, Irvine Medical Center, 101 The City Dr, Orange, CA 92868, USA
    Anticancer Res 23:3985-90. 2003
    ..Ovarian carcinoma metastases occur when the malignant cells establish new colonies on the peritoneal surface. This study was undertaken to determine whether mesothelial cell hyaluronan affects tumor cell motility...
  8. ncbi Reversible transformation by v-sis: a model cell line for analysis of transformation by antisense methods
    P M Carpenter
    Department of Pathology, University of California, San Diego, La Jolla 92093
    Antisense Res Dev 1:289-95. 1991
    ..Cells from the remaining and larger, 0.5 +/- 0.7 gram, tumors did not revert by any criteria. This suggests that subsequent tumor growth is maintained by acquisition of irreversible change(s) that occurs at high frequency in vivo...
  9. ncbi Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
    ..Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects...
  10. ncbi Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli
    Rita S Mehta
    Department of Internal Medicine, University of California, Irvine, CA, USA
    Clin Breast Cancer 9:56-9. 2009
    ..Subsequently, the patient received carboplatin and albumin-bound paclitaxel and experienced complete remission...
  11. ncbi Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab
    Shadfar Bahri
    Tu and Yuen Center for Functional Onco Imaging, University of California, Irvine, USA
    Ann Surg Oncol 16:1619-28. 2009
    ..To investigate the impact of antiangiogenic therapy with bevacizumab on pathological response and the diagnostic performance of magnetic resonance imaging (MRI) in breast cancer patients...
  12. ncbi Measuring microvascular density in tumors by digital dissection
    Michael Samoszuk
    Hematology Oncology Center, Quest Diagnostics, Inc, San Juan Capistrano, California, USA
    Anal Quant Cytol Histol 24:15-22. 2002
    ..To develop and validate a digital dissection techniquefor measuring the cross-sectional area of blood vessels in histologic sections of tumors routinely stained with hematoxylin and eosin...
  13. ncbi MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy
    Jeon Hor Chen
    Tu and Yuen Center for Functional Onco Imaging, University of California Irvine, Irvine, California 92697, USA
    Cancer 112:17-26. 2008
    ....
  14. ncbi C1qR(P), a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue
    M I Fonseca
    Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA
    J Leukoc Biol 70:793-800. 2001
    ..The predominant presence of C1qR(P) in endothelial cells, while compatible with a phagocytic role in host defense and/or clearance of cellular material, suggests other possible novel roles for this receptor...
  15. ncbi Rapid, complete and reversible transformation by v-sis precedes irreversible transformation
    D Mercola
    Department of Pathology, University of California, San Diego, La Jolla 92093
    Oncogene 7:1793-803. 1992
    ..Thus an early event of a multistep process stimulated by v-sis-dependent transformation best accounts for the sum of results...
  16. ncbi TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases
    Will Yarosh
    Department of Pediatrics, Division of Human Genetics, University of California, Irvine, California 92697, USA
    Cancer Res 68:693-9. 2008
    ..TBX3 repression to its targets is dependent on HDAC activity. TBX3 may serve as a biomarker for breast cancer and have significant applications in both breast cancer diagnosis and treatment...
  17. ncbi Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent
    Charles P Theuer
    Division of Surgical Oncology, Department of Surgery, University of California, Irvine, California, USA
    Am Surg 72:332-8. 2006
    ..If the biology of gastric cancer in the Far East is less aggressive than that in the United States, it is likely that treatments need to be individualized...
  18. ncbi Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea
    Kenneth G Linden
    Department of Dermatology, University of California, Irvine, 101 The City Drive, Orange, CA 92868, USA
    Recent Results Cancer Res 163:165-71; discussion 264-6. 2003
    ....
  19. ncbi Paranuaclear E-cadherin in gastric adenocarcinoma
    Philip M Carpenter
    Department of Pathology, University of California, Irvine Medical Center, Orange 92868, USA
    Am J Clin Pathol 118:887-94. 2002
    ....
  20. ncbi Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy
    Jeon-Hor Chen
    J Clin Oncol 25:5667-9. 2007
  21. ncbi VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model
    Martin N Nakatsu
    Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California 92697, USA
    Lab Invest 83:1873-85. 2003
    ..We conclude that the diameter of new capillary sprouts can be determined by the local concentration of VEGF and that the action of VEGF on angiogenic EC in this assay is critically dependent on signaling through VEGFR-2...
  22. ncbi The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi
    Jenny L Hardison
    Department of Molecular Biology and Biochemistry, 3205 McGaugh Hall, University of California at Irvine, Irvine, CA 92697 3900, USA
    Infect Immun 74:125-34. 2006
    ..cruzi infection...